Literature DB >> 26919561

Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model.

Pierre Bize1, Rafael Duran1, Katrin Fuchs1, Olivier Dormond1, Julien Namur1, Laurent A Decosterd1, Olivier Jordan1, Eric Doelker1, Alban Denys1.   

Abstract

Purpose To measure plasmatic sunitinib concentration (PSC) and intratumoral sunitinib concentration (ITSC) after transcatheter arterial chemoembolization (TACE) with two different sizes of sunitinib-eluting beads (SEBs) in rabbits with VX2 hepatic allografts and to investigate treatment effects on vascular endothelial growth factor receptor type 2 (VEGFR2) phosphorylation, tumor volume, and histopathologic changes. Materials and Methods The protocol was approved by the French Ethics Committee for Animal Experiments (Comité d'Ethique en Expérimentation Animale du Centre INRA de Jouy-en-Josas et AgroParisTech, or COMETHEA, approval no. 11/028). Two experiments were performed. In the first, seven animals received 0.05 mL of 100-300-μm SEBs (1.5 mg of sunitinib) in the hepatic artery, and six animals received saline injections. In the second, eight animals received 0.05 mL of 70-150-μm SEBs (1.5 mg of sunitinib), seven received 0.05 mL of 70-150-μm unloaded beads, and seven received oral sunitinib (6 mg every day). Tumor size was monitored with ultrasonography. PSC, ITSC, and phosphorylation of VEGFR2 were assessed on days 1 and 14. After the animals were sacrificed, histopathologic analysis was performed. The Kruskal-Wallis test, Mann-Whitney U test, and Fisher exact test were used to look for statistically significant differences between groups. Results Maximum PSC after TACE with 100-300-μm SEBs was 0.002 μg/mL on day 1. ITSC was 17.8 μg/g on day 1 and 0.16 μg/g on day 14. After TACE with 70-150-μm SEBs, ITSC was 40.4 μg/g on day 1 and 27.4 μg/g on day 14. Phosphorylation of VEGFR2 was inhibited until day 14 after TACE with both sizes of SEBs. The size of VX2 tumors treated with 70-150-μm SEB TACE increased less (-2%) than that of tumors treated with unloaded beads (+42%) and oral sunitinib (6 mg every day; +1853%; P = .044). Conclusion SEB TACE resulted in minimal PSC, high ITSC, and sustained VEGFR2 phosphorylation inhibition until day 14. (©) RSNA, 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26919561     DOI: 10.1148/radiol.2016150361

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  12 in total

Review 1.  Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions.

Authors:  Meaghan S Dendy; Johannes M Ludwig; Stacey M Stein; Hyun S Kim
Journal:  Liver Cancer       Date:  2019-01-16       Impact factor: 11.740

Review 2.  Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?

Authors:  Thierry de Baere; Lambros Tselikas; Frederic Deschamps; Valerie Boige; Michel Ducreux; Antoine Hollebecque
Journal:  Hepat Oncol       Date:  2016-03-23

Review 3.  Localized targeted antiangiogenic drug delivery for glioblastoma.

Authors:  Gregory D Arnone; Abhiraj D Bhimani; Tania Aguilar; Ankit I Mehta
Journal:  J Neurooncol       Date:  2018-01-11       Impact factor: 4.130

4.  Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models.

Authors:  Nirmitha I Herath; Flavien Devun; Aurélie Herbette; Marie-Christine Lienafa; Philippe Chouteau; Jian-Sheng Sun; Marie Dutreix; Alban Denys
Journal:  Eur Radiol       Date:  2017-04-03       Impact factor: 5.315

5.  Donafenib-Loaded Callispheres Beads Embolization in a VX2 Liver Tumor: Investigating Efficacy, Safety, and Improvement of Tumor Angiogenesis After Embolization.

Authors:  Tongqiang Li; Qin Shi; Jiacheng Liu; Yingliang Wang; Chen Zhou; Chaoyang Wang; Shuguang Ju; Songjiang Huang; Chongtu Yang; Yang Chen; Yaowei Bai; Bin Xiong
Journal:  J Hepatocell Carcinoma       Date:  2021-12-03

6.  Establishment of human metastatic colorectal cancer model in rabbit liver: A pilot study.

Authors:  Veronica Prieto; Johannes M Ludwig; Alton B Farris; Ganji Purnachandra Nagaraju; Taoreed O Lawal; Bassel El-Rayes; Hyun S Kim
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

7.  Vandetanib-eluting Radiopaque Beads: In vivo Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver Embolization.

Authors:  Alban Denys; Peter Czuczman; David Grey; Zainab Bascal; Rhys Whomsley; Hugh Kilpatrick; Andrew L Lewis
Journal:  Theranostics       Date:  2017-06-01       Impact factor: 11.556

8.  In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma-A pilot study.

Authors:  Steven Lahti; Johannes M Ludwig; Minzhi Xing; Lingyi Sun; Dexing Zeng; Hyun S Kim
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

9.  The Mechanism of Computed Tomography-Guided 125I Particle in Treating Lung Cancer.

Authors:  Jianzhong Cheng; Shaozeng Ma; Guanghua Yang; Lisen Wang; Wei Hou
Journal:  Med Sci Monit       Date:  2017-01-17

10.  Development and evaluation of an ultrasound-triggered microbubble combined transarterial chemoembolization (TACE) formulation on rabbit VX2 liver cancer model.

Authors:  Doyeon Kim; Jae Hwan Lee; Hyungwon Moon; Minkyu Seo; Hyounkoo Han; Hongkeun Yoo; Howon Seo; Jingu Lee; Sujung Hong; Pilhan Kim; Hak Jong Lee; Jin Wook Chung; Hyuncheol Kim
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.